Case Report: Progressive interstitial lung disease secondary to Sjögren’s disease in a patient with inclusion body myositis complicated by dysphagia—a multidisciplinary approach and therapeutic challenges

We present the case of a 78-year-old man with a complex overlap of inclusion body myositis (IBM) and Sjögren’s disease (SjD), complicated by interstitial lung disease (ILD) and esophageal dysfunction. The patient’s neuromuscular decline was managed with periodic intravenous immunoglobulins (IVIG), while his progressive ILD required a combined immunosuppressive and antifibrotic regimen, including prednisone. This case underscores the diagnostic and therapeutic challenges in managing autoimmune overlap syndromes, particularly the rare coexistence of IBM and SjD-related ILD. We highlight the rationale behind the treatment strategy and the importance of a tailored, multidisciplinary approach in addressing both muscular and pulmonary manifestations.

• Publication year

  2025

• Venue

  Frontiers in Medicine

• Publication date

  2025-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fmed.2025.1683606PMID 41306496PMCID 12643880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nerandomilast in Patients with Progressive Pulmonary Fibrosis.

  2025cited by this paper
• 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

  2024cited by this paper
• Prevalence of Progressive Fibrosing Interstitial Lung Disease in Patients with Primary Sjogren Syndrome

  2024cited by this paper
• Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis.

  2024influential reference
• Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

  2024cited by this paper
• Potential common molecular mechanisms between Sjögren syndrome and inclusion body myositis: a bioinformatic analysis and in vivo validation

  2023cited by this paper
• Inclusion body myositis and Sjögren’s syndrome: the association works both ways

  2022cited by this paper
• Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

  2020cited by this paper
• Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS.

  2020influential reference
• Interstitial lung disease in Sjögren's syndrome: a clinical review.

  2020cited by this paper
• Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

  2019cited by this paper
• 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts

  2017cited by this paper
• Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis–Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II

  2017cited by this paper
• Inclusion Body Myositis

  2012cited by this paper
• Inclusion body myositis associated with Sjögren’s syndrome

  2012cited by this paper
• Long-term observational study of sporadic inclusion body myositis.

  2011cited by this paper
• Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

  2007cited by this paper
• Cyclophosphamide in scleroderma lung disease.

  2006cited by this paper
• Cyclophosphamide in scleroderma lung disease.

  2006cited by this paper
• Cyclophosphamide in scleroderma lung disease.

  2006cited by this paper

• No citing papers are available for this paper.